Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan

INTRODUCTION: Fatty acid oxidation disorders (FAODs) are rare diseases caused by defects in mitochondrial fatty acid oxidation (FAO) enzymes. While the efficacy of bezafibrate, a peroxisome proliferator-activated receptor agonist, on the in vitro FAO capacity has been reported, the in vivo efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Kenji, Shiraishi, Hideaki, Oki, Eishin, Ishige, Mika, Fukao, Toshiyuki, Hamada, Yusuke, Sakai, Norio, Ochi, Fumihiro, Watanabe, Asami, Kawakami, Sanae, Kuzume, Kazuyo, Watanabe, Kenji, Sameshima, Koji, Nakamagoe, Kiyotaka, Tamaoka, Akira, Asahina, Naoko, Yokoshiki, Saki, Miyakoshi, Takashi, Ono, Kota, Oba, Koji, Isoe, Toshiyuki, Hayashi, Hiroshi, Yamaguchi, Seiji, Sato, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852296/
https://www.ncbi.nlm.nih.gov/pubmed/29552494
http://dx.doi.org/10.1016/j.ymgmr.2018.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852296/
https://www.ncbi.nlm.nih.gov/pubmed/29552494
http://dx.doi.org/10.1016/j.ymgmr.2018.02.003

Ejemplares similares